AntiCancer Inc.Cancer Inc. Has Received a New Patent That Revolutionizes Individualized Mouse Models of Human Cancer Patients by Increasing the Patient-tumor Establishment Rate in Mice to Close to 100%
29 Jan 2024
SAN DIEGO--(BUSINESS WIRE)-- AntiCancer Inc.Cancer Inc. announced it has just received US Patent 11,871,731 that describes a method to increase the rate of establishment of patient tumors in mice to close to 100%. Previously the establishment rates were much lower, in many cases only 10-20% in laboratories around the world. “The new method allows, for the first time, large scale and commercial success of establishing mouse models for each cancer patient to individualize and optimize their cancer therapy, as well as banking their tumors after establishment for future therapy,” said Chihiro Hozumi, co-inventor of the patent and General Manager of AntiCancerCancer’s Japanese subsidiary, AntiCancerCancer Japan.
“The new method is especially important as almost all cancer patients can now have their own individualized clinically-concordant PDOX mouse model,” said AntiCancerCancer Senior Mouse-Model Scientist Jose Reynoso. “The new method facilitates the discovery of effective cancer drugs, since many more mouse models of cancer with patient tumors will be available for testing of novel cancer drugs,” said AntiCancerCancer Senior Scientist Qinghong Han.
AntiCancer Inc.Cancer Inc. of San Diego was established in 1984 and is celebrating its 40th anniversary. AntiCancerCancer is a world leader in developing individualized cancer therapy, including contract research, using its proprietary PDOX mouse model which it has developed since 1987, and most closely represents the cancer patient.
View source version on businesswire.com:
Contacts
Qinghong Han, MD
all@anticancer.com
Source: AntiCancer Inc.Cancer Inc.
View this news release online at:
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.